RecruitingNCT06541652
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
Studying Angiosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Federation Francophone de Cancerologie Digestive
- Principal Investigator
- jean-charles nault, PrFederation Francophone de Cancerologie Digestive
- Enrollment
- 150 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2031
Study locations (30)
- CHU Amiens picardie, Amiens, France
- Chu Angers, Angers, France
- Ch - Centresimone Veil de Beauvais, Beauvais, France
- Chu Jean Minjoz, Besançon, France
- Ch Bethune Beuvry, Béthune, France
- Avicenne, Bobigny, France
- Cote de Nacre, Caen, France
- Centre Hospitalier, Calais, France
- Chu de Clichy Hopital Beaujon, Clichy, France
- Centre Hospitalier Universitaire Henri Mondor, Créteil, France
- CHU, Dijon, France
- Chu Grenobles Alpes, La Tronche, France
- Centre Hospital Universitaire de lille, Lille, France
- Longjumeau Ch Nord Essone, Longjumeau, France
- Ch Edouard Herriot, Lyon, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Société Nationale Française de Gastroentérologie
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06541652 on ClinicalTrials.govOther trials for Angiosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS
- RECRUITINGPHASE2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPHASE2NCT06673628Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsNational Cancer Center, Japan
- RECRUITINGPHASE1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc.
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group
- RECRUITINGPHASE2NCT06277154MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue SarcomaHRYZ Biotech Co.